evERA
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
- NCT05306340 ↗
- Active, not recruiting
- Genentech, Inc.
- Deep
We haven't built an HCP commentary report on evERA (giredestrant, tamoxifen and 5 more in Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on evERA so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 139 | |
| YouTube | 30 | |
| Podcasts | 13 | |
| X videos | 6 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Patients With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- Interventions
- Giredestrant; Exemestane; Fulvestrant; Tamoxifen; Everolimus; LHRH Agonist; Dexamethasone Mouth Rinse
- Arms
- Giredestrant plus Everolimus · Experimental
- Physician's Choice of Endocrine Therapy plus Everolimus · Active comparator
- Enrollment
- 373
- Primary outcomes
- Progression-Free Survival, as Determined by the Investigator According to RECIST v1.1, in the ESR1m Subpopulation and ITT Population
- Sponsor
- Genentech, Inc.
- Start
- Aug 3, 2022
- Primary completion
- Jul 16, 2025
- Results posted
- No
- Registry record
- NCT05306340 · updated Jun 17, 2026
Publications
linked from the registry- Mayer EL, Tolaney SM, Martin M, Vidal GA, Moscetti L, Jhaveri KL, Brufsky A, Gradishar WJ, Schneeweiss A, Niikura N, Favret A, Alfie M, Lee KS, Khan S, Feldman MB, Day BM, Lam LH, Darbonne WC, Shah MD, Griffiths KL, DiLallo G, Perez-Moreno PD, Rugo HS; evERA Breast Cancer Investigators. Giredestrant plus Everolimus in Advanced Breast Cancer. N Engl J Med. 2026 Oct 1;395(13):1285-1298. doi: 10.1056/NEJMoa2602457. PubMed 42814929